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restricted to plasma for fractionation. 
Some protection against blood dona-
tions from HEV-infected persons may 
occur because HEV and malaria are co-
endemic to many countries. Our find-
ings showed a higher HEV seropreva-
lence among donors with prior malaria 
or diarrhea deferrals; thus, malaria- and 
diarrhea-related screening questions 
may reduce contributions from donors 
with travel-associated HEV infection.
Our findings showed HEV expo-
sure in travelers and nontravelers, sug-
gesting the possibility of imported and 
locally acquired HEV in Australia. Pri-
or HEV exposure was higher in donors 
who were temporarily excluded from 
donating blood on previous donation 
attempts, suggesting the current man-
agement strategy in Australia is par-
tially effective in minimizing any risk 
of HEV transmission through blood 
transfusion. However, the presence of 
HEV IgG in donors who reported no 
overseas travel and/or no prior related 
deferrals, coupled with the knowledge 
that asymptomatic infection is possible, 
suggests that additional safety precau-
tions may be warranted.
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Helicobacter  
cinaedi Infection  
of Abdominal Aortic 
Aneurysm, Japan
To the Editor: Infected ab-
dominal aortic aneurysm (IAAA) 
is uncommon, but life-threatening; 
the mortality rate ranges from 25% 
to 30% (1,2). Identification of the 
pathogen is essential for diagno-
sis and treatment. Previous studies 
have shown that species of the gen-
era Salmonella, Staphylococcus, and 
Streptococcus are the most common 
pathogens associated with IAAA, but 
a causative organism is not identified 
in 14%–40% of patients (1,2). He-
licobacter cinaedi has mainly been 
isolated from immunocompromised 
patients with bacteremia, cellulitis, 
and septic arthritis (3,4). Here, we 
report 3 cases of IAAA caused by H. 
cinaedi detected by 16S ribosomal 
RNA (16S rRNA) gene analysis.
The 3 patients (case-patients 1–3) 
were referred to Tohoku University 
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Hospital, Sendai, Japan, for surgical 
treatment of IAAA in 2013. None 
had a history of disease known to 
cause immunodeficiency. Because 
their abdominal aneurysms enlarged 
rapidly, all 3 patients underwent re-
section of the aneurysm and exten-
sive local debridement and irrigation. 
Histopathologic examination of the 
surgical specimens revealed severe 
atherosclerosis and inflammation, 
consistent with a diagnosis of IAAA. 
For each case-patient, blood culture 
(BacT/ALERT; bioMérieux Industry, 
Tokyo, Japan) was negative, as was 
culture of surgically removed tis-
sue on HK semisolid agar (Kyokuto 
Pharmaceutical Industrial Co., Ltd., 
Tokyo, Japan) at 35°C under aerobic 
conditions for 7 days for enrichment 
of microorganisms, and on choco-
late agar at 35°C under 5% CO2 for 
48 h. We then used 16S rRNA gene 
analysis to identify a pathogen. We 
extracted DNA from resected tissues 
using a QIAamp DNA Mini kit (QIA-
GEN K.K., Tokyo, Japan), amplified 
it using PCR, and sequenced it using 
universal primers for 16S rRNA (5). 
We used the EzTaxon-e Database for 
sequence analysis (http://eztaxon-e.
ezbiocloud.net/), which revealed that 
the 16S rRNA gene sequence of bac-
teria in the aneurysmal tissues was 
identical to that of H. cinaedi. 
For case-patient 3, we cultured mi-
croaerophilic tissue at 35°C using Tryp-
ticase Soy Agar II with 5% sheep blood 
(Kyokuto Pharmaceutical Industrial 
Co.) and an Anaero Pouch-MicroAero 
(Mitsubishi Gas Chemical Co., Inc., 
Tokyo, Japan) to detect H. cinaedi. We 
observed bacterial colonies, after Gram 
staining, which showed gram-negative 
spiral rods. By 16S rRNA gene analy-
sis, we confirmed that the isolate was 
H. cinaedi. 
For each of the 3 case-patients, 
species identification was further 
confirmed by sequence analysis of 
23S ribosomal RNA (23S rRNA) 
(DNA Data Bank of Japan: http://
blast.ddbj.nig.ac.jp/blastn?lang = ja) 
and amplification of the gyrB gene 
region that is specific to H. cinaedi 
(6,7). In samples from the 3 patients, 
there were mutations of the 23S rRNA 
gene and amino acid substitutions in 
GyrA related to macrolide and fluo-
roquinolone resistance, respectively 
(6,8). After identifying the patho-
gen, we selected antimicrobial agents 
based on the reported drug suscep-
tibility profile of H. cinaedi (6,8). 
The patients survived and are being 
followed up as outpatients. Clinical 
and molecular characteristics of the 3 
cases of IAAA with H. cinaedi infec-
tion are shown in the Table.
Although the high negative cul-
ture rate for pathogens causing IAAA 
had been explained by prolonged 
preoperative antimicrobial drug ther-
apy (2), another possibility is that H. 
cinaedi may be a causative organism. 
Earlier research has suggested that H. 
cinaedi infections can remain undi-
agnosed or be incorrectly diagnosed 
because of difficulty in isolating this 
microorganism (9). H. cinaedi grows 
slowly under microaerophilic condi-
tions, but no current standard labora-
tory methods result in a diagnosis of 
this pathogen (6,7,9). We isolated H. 
cinaedi from surgically removed tis-
sue from case-patient 3 by microaero-
philic culture after taking this patho-
gen into consideration. For diagnosis 
of H. cinaedi infections, methods 
leading to accurate identification by 
clinical microbiological laboratories 
are needed. Currently, H. cinaedi is 
identified by molecular analysis of the 
16S rRNA gene (6,7,10). In addition, 
matrix-assisted laser desorption/
ionization–time-of-flight mass 
spectrometry (MALDI-TOF MS) 
(10), may become a useful tool for 
this purpose. 
Standard breakpoints of antimi-
crobial drugs for H. cinaedi have not 
been defined, but all isolates in this 
study had mutations that indicated re-
sistance to macrolides and fluoroqui-
nolones. For adequate treatment for 
H. cinaedi infections, guidelines for 
selection of antimicrobial drugs and 
surveillance of its antimicrobial sus-
ceptibility profile are required.
During November 2012–Novem-
ber 2013, 8 patients underwent their 
first operation for IAAA at the uni-
versity hospital. We used 16S rRNA 
gene analysis of surgical tissues and 
culture of blood and tissue specimens 
to detect pathogens (data not shown). 
Identification of H. cinaedi in 3 of 8 
patients suggests that it could be a 
prevalent pathogen related to IAAA. 
Taking such information into consid-
eration could affect the prognosis of 
many patients. Accordingly, tissue 
should be cultured while consider-
ing H. cinaedi infection in patients 
with IAAA. H. cinaedi colonizes the 
gastrointestinal tract, and bacterial 
translocation may lead to bacteremia 
associated with mucosal damage (4). 
However, the route of transmission 
and reason most H. cinaedi infections 
have been reported in Japan are un-
clear. To clarify the relationship be-
tween H. cinaedi and IAAA, further 
clinical and epidemiologic studies are 
needed. Meanwhile, we recommend 
clinical consideration of H. cinaedi 
infection, use of appropriate labora-
tory procedures to identify cases, and 
development of treatment guidelines.
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Table.	Clinical	characteristics	of	3	patients	with	Helicobacter cinaedi infected	abdominal	aortic	aneurysms and	molecular	
characteristics	of	isolates,	Japan* 
Characteristic Case-patient	1 Case-patient	2 Case-patient	3 
Age,	y/sex 64/M 59/M 62/M 
Underlying	diseases Hypertension,	hyperlipidemia None History	of	myocardial	infarction 
Risk	factors	for	infection None None None 
Clinical	signs	and	symptoms	
before	surgery 
Fever,	back	pain Fever,	abdominal	pain Low	back	pain 
CT	results    
 Site of aneurysm Infrarenal	abdominal,	bilateral	
common	iliac,	internal	iliac,	L 
















Surgical	management In situ grafting In situ grafting In situ grafting 
Microbiological	diagnosis 
 Blood	culture – – – 
 Tissue	culture – – +‡ 
 rRNA	gene	sequence	similarity,	%§ 
  16S 99.8 99.6 99.6 
  23S 99.8 99.8 99.8 
 Amplification	of	gyrB specific	to	 
 H. cinaedi 
+ + + 








MLST ST15	(CC7) ST10	(CC9) ST10	(CC9) 
Mutation	of	23S	rRNA	gene	and	
amino	acid	substitutions	in	GyrA 
2018	AG	and	T84I	D88G 2018	AG	and	T84I 2018	AG	and	T84I 
Antimicrobial	therapy dosage	and	
duration 
   





























Postoperative	complications None None None 
Outcome Survived Survived Survived 
*CT,	computed	tomography;	+,	positive;	–,	negative;	L,	left;	R,	right;	MLST,	multilocus sequence	typing;	ST,	sequence	type;	CC,	clonal	complex;	A,	
adenine;	G,	guanine;	T,	threonine;	I,	isoleucine;	D,	aspartic	acid;	G,	glycine. 
†Aortic arch was replaced 5 weeks after the abdominal operation. 
‡Species unidentifiable under microaerophilic conditions. 
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Hepatitis E Virus 
from Raw Pork  
Liver Sausage, 
France
To the Editor: The number of 
sporadic autochthonous cases of acute 
hepatitis E is increasing in many in-
dustrialized countries (1). These cases 
involve hepatitis E virus (HEV) geno-
types 3 and 4, which are zoonotic. 
Although risk for foodborne transmis-
sion from pork is now recognized, we 
report here direct HEV transmission 
through ingestion of raw pig liver sau-
sages (figatellu [plural: figatelli]) in 
southeastern France.
The index case-patient was a 
45-year-old woman from Hyères 
(southeastern France) who had no 
underlying medical condition. She 
visited her general practitioner on 
December 17, 2013, reporting 3 days 
of weakness. Acute hepatitis was 
diagnosed 2 days later on the basis 
of elevated liver enzymes (alanine 
aminotransferase 1,265 IU/L [refer-
ence <35 IU/L]) and bilirubin (65 
μmol/L [reference <17 μmol/L]). Se-
rum markers for acute hepatitis A, B, 
and C; cytomegalovirus; and Epstein-
Barr virus were negative. Jaundice 
appeared on December 19, and the 
patient was referred to the Medical 
Unit of Hyères for additional investi-
gations. A serum sample collected on 
December 20 tested positive for HEV 
RNA; viral load was 3.3 log10 IU/
mL (Ceeram, La Chapelle sur Erdre, 
France), and IgM and IgG against 
HEV were found (Wantai, Beijing, 
China), which led to the diagnosis of 
acute hepatitis E. The HEV genotype 
was 3f, as determined from the phy-
logenetic analysis of a portion of the 
open reading frame (ORF) 2 (2). The 
index case-patient recovered by the 
end of January; HEV viremia was un-
detectable on January 17, 2014.
The index case-patient and her 
family regularly ate figatelli (raw pork 
liver sausages) made in Corsica. The 
patient had most recently eaten figatelli 
at a lunch with 8 family members on 
October 28, 2013, seven weeks before 
illness onset. After receiving informed 
consent, we conducted laboratory in-
vestigations of samples from the other 
family members; tests included HEV 
serology and HEV RNA detection in 
serum and fecal samples. Samples were 
obtained from family members during 
January 8–21, 2014 (41–54 days after 
the lunch). Positive HEV IgM and de-
tectable HEV RNA were found in the 
serum of the index case-patient’s daugh-
ter, who was asymptomatic. Because 
the sample was tested 10 weeks after 
the family lunch, the daughter’s HEV 
viral load was too low to enable se-
quence characterization and clustering 
of HEV strains. Three other family 
members were IgG positive for HEV, 
indicating previous HEV infection. 
Leftover sausages had been kept frozen 
and were available for HEV testing.
HEV RNA was detectable from 
the leftover sausages, and HEV se-
quences were amplified in 2 different 
genomic regions (ORF1: RNA-depen-
dent RNA polymerase and ORF2), as 
described previously (2). Comparison 
with the index case-patient’s sequenc-
es showed 100% nt identity for both 
regions (Figure). Samples of food and 
samples from the index case-patient 
were analyzed in 2 independent labo-
ratories to avoid any cross-contamina-
tion. The level of contamination of the 
figatellu was ≈4.8 104 copies of HEV 
RNA/g of sausage (3).
Figatellu, a dried sausage, contains 
30% pork liver and no heating step oc-
curs during its manufacture. Usually 
deep cooking is recommended on the 
package, but consumers might not fol-
low the cooking recommendation; also, 
figatelli can be sold in small local shops 
with no label. In the instance reported 
here, the figatellu was sold without any 
warning label and was eaten raw.
That HEV was transmitted 
through ingestion of contaminated 
food is supported by the following 
evidence. First, 3 case reports have 
provided direct evidence of HEV 
transmission through ingestion of 
contaminated animal food products 
with identical or near identical se-
quences between the patients and the 
contaminated food they ate. Two cases 
occurred in the early 2000s in Japan 
through consumption of grilled wild 
boar (4) or sashimi of Sika deer (5); 
the third, reported recently in Spain, 
was transmitted through ingestion of 
pig meat (6). Second, HEV widely in-
fects domestic pigs and wild boar (7). 
Third, swine and human HEV strains 
have genetic similarities and, in 
